Road to RSNA 2023: Molecular Imaging

This is just the third year that RSNA has offered a dedicated track on nuclear medicine and molecular imaging, with eight scientific sessions covering research in prostate cancer imaging, breast cancer, cardiovascular and pulmonary imaging, and more. There will be also 30 educational courses and 14 poster sessions. Notably, this is the first year a scientific session is being offered that covers advances in AI in nuclear medicine. Presentations on PET imaging in prostate cancer – an approach that is witnessing widespread adoption – include an array of studies on prostate-specific membrane antigen (PSMA)-based radiotracers. However, experts note that up to 10% of prostate cancers do not express PSMA. Thus, we highlighted a study in this year’s Road to RSNA that will present phase II/III trial results of a gallium-68 (Ga-68) tracer that targets gastrin-releasing peptide receptors (GRPR), which are also overexpressed in these tumors.Despite these advances, prognostication of prostate cancer patient outcomes remains challenging. Can AI help? At least one study suggests so, with a deep-learning model to be presented that predicts patient treatment response based on F-18 DCFPyL PSMA-PET/CT imaging.Still, PET imaging in breast cancer may be among this year’s hottest topics, with studies suggesting FDG-PET/MRI may be reliable in newly diagnosed patients and another revealing which potential tracer is more effective in women with metastatic lesions, namely F-18 fluciclovine or...
Source: AuntMinnie.com Headlines - Category: Radiology Authors: Tags: 2023 2023 Molecular Imaging Preview Source Type: news